Search company, investor...


Founded Year



Unattributed VC | Dead

Total Raised


Last Raised


About Genstruct

Genstruct is a computational systems biology company that delivers high impact, real time, testable biological insights to enable mechanism-based drug discovery and development for partners including leading pharmaceutical and biotechnology companies.

Headquarters Location

One Alewife Center Suite 100

Cambridge, Massachusetts, 02140,

United States


Missing: Genstruct's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Genstruct's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Genstruct Patents

Genstruct has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Biological databases, Data management, Gene expression, Information systems, Bioinformatics


Application Date


Grant Date



Related Topics

Biological databases, Data management, Gene expression, Information systems, Bioinformatics



Genstruct Frequently Asked Questions (FAQ)

  • When was Genstruct founded?

    Genstruct was founded in 2002.

  • Where is Genstruct's headquarters?

    Genstruct's headquarters is located at One Alewife Center, Cambridge.

  • What is Genstruct's latest funding round?

    Genstruct's latest funding round is Unattributed VC.

  • How much did Genstruct raise?

    Genstruct raised a total of $7.5M.

  • Who are the investors of Genstruct?

    Investors of Genstruct include Flagship Pioneering, Pappas Ventures and Genstruct.

  • Who are Genstruct's competitors?

    Competitors of Genstruct include Nuevolution, Blue Sky BioServices, Zalicus, BioSeek, Bg Medicine and 14 more.

Compare Genstruct to Competitors


Opulus, Ltd. is a biotechnology company focused on the development of new measurement systems based on hyphenated Quartz Crystal Microbalance for molecular biology, drug discovery, and the development of new materials for drug delivery and cosmetic treatment based on high resolution visco-elastic kinetics and in-situ cytotoxicity.

Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

Montana Molecular Logo
Montana Molecular

Montana Molecular was founded in 2004 to develop and commercialize fluorescent proteins (FPs) for live cell imaging applications. The technology that underlies this effort was originally conceived by Thomas Hughes at Yale University. Dr. Hughes is now the head of the Department of Cell Biology and Neuroscience at Montana State University. The Company has used this technology to develop several new read-outs for pharmaceutical and biotechnology applications, including genetically encoded fluorescent markers, a system for detecting protein-protein interaction, and biosensors for cell-based high throughput drug discovery.

AVIVA Biosciences

AVIVA develops enabling drug discovery technoSlogies by combining biochips with cell biology.

DC Biosciences Logo
DC Biosciences

DC Biosciences, formerly Dundee Cell Products, provides pharmaceutical and biotech companies with novel technologies and proteomics services to accelerate the development of safer drugs.


Bionucleon is a drug discovery company with a technology platform to produce olibo-based therapeutics. Bionucleon's business strategy is based on a three-branch approach:nnUsing its technology, the company aims to build its own pipeline of therapeutics for inflammatory diseases and angiogenic disorders. Bionucleon collaborates with pharmaceutical and biotechnology companies to create new oligo-based therapeutics against targets of the partner's choosing. Bionucleon generates products for out-licensing at different research and development stages. Collaborative partnerships and out-licensing provide upfront and milestone payments, and generate downstream revenue through product royalties. This approach maximizes the return on the company's nknow-how and technical capability. Through drug discovery partnering in addition to developing its own product pipeline, Bionucleon aims to build corporate value and aims to reduce the financial risk as it moves forward.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.